This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blasberg, R. G. Articles by Leenders, K. L. Search for Related Content PubMed PubMed Citation Articles by Blasberg, R. G. Articles by Leenders, K. L.

Imaging Brain Tumor Proliferative Activity with [¹²⁴I]Iododeoxyuridine¹

Cotzias Neuro-Oncology Laboratory [R. G. B., B. B.] and Radiochemistry/Cyclotron Core Facility [R. D. F.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021; PET Program [U. R., I. G., P. V., J. M., R. P. M., K. L. L.] and Institute of Medical Radiobiology [N. E. A. C., R. W., J. K.], Paul Scherrer Institute, Villigen CH-5232, Switzerland; Department of Neurosurgery, University Hospital, Zürich CH-8091, Switzerland [K. v. A., Y. Y.]; Department of Neurosurgery, Cantonal Hospital, Aarau CH-5001, Switzerland [H. L.]; and Department of Nuclear Medicine, University Hospital, Essen, D-45122, Germany [E. J. K.]

Iododeoxyuridine (IUdR) uptake and retention was imaged by positron emission tomography (PET) at 0–48 min and 24 h after administration of 28.0–64.4 MBq (0.76–1.74 mCi) of [¹²⁴I]IUdR in 20 patients with brain tumors, including meningiomas and gliomas. The PET images were directly compared with gadolinium contrast-enhanced or T2-weighted magnetic resonance images. Estimates for IUdR-DNA incorporation in tumor tissue (Ki) required pharmacokinetic modeling and fitting of the 0–48 min dynamically acquired data to correct the 24-h image data for residual, nonincorporated radioactivity that did not clear from the tissue during the 24-h period after IUdR injection. Standard uptake values (SUVs) and tumor:brain activity ratios (Tm:Br) were also calculated from the 24-h image data. The Ki, SUV, and Tm/Br values were related to tumor type and grade, tumor labeling index, and survival after the PET scan.

The plasma half-life of [¹²⁴I]IUdR was short (2–3 min), and the arterial plasma input function was similar between patients (48 ± 12 SUV*min). Plasma clearance of the major radiolabeled metabolite ([¹²⁴I]iodide) varied somewhat between patients and was markedly prolonged in one patient with renal insufficiency. It was apparent from our analysis that a sizable fraction (15–93%) of residual nonincorporated radioactivity (largely [¹²⁴I]iodide) remained in the tumors after the 24-h washout period, and this fraction varied between the different tumor groups. Because the SUV and Tm:Br ratio values reflect both IUdR-DNA incorporated and exchangeable nonincorporated radioactivity, any residual nonincorporated radioactivity will amplify their values and distort their significance and interpretation. This was particularly apparent in the meningioma and glioblastoma multiforme groups of tumors.

Mean tumor Ki values ranged between 0.5 ± 0.9 (meningiomas) and 3.9 ± 2.3 µl/min/g (peak value for glioblastoma multiforme, GBM). Comparable SUV and Tm:Br values at 24 h ranged from 0.13 ± 0.03 to 0.29 ± 0.19 and from 2.0 ± 0.6 to 6.1 ± 1.5 for meningiomas and peak GBMs, respectively. Thus, the range of values was much greater for Ki (8-fold) compared with that for SUV (2.2-fold) and Tm:Br (3-fold). The expected relationships between Ki, SUV, and Tm:Br and other measures of tumor proliferation (tumor type and grade, labeling index, and patient survival) were observed. However, greater image specificity and significance of the SUV and Tm:Br values would be obtained by achieving greater washout and clearance of the exchangeable fraction of residual (background) radioactivity in the tumors, i.e., by increased hydration and urinary clearance and possibly by imaging later than 24 h after [¹²⁴I]IUdR administration.

This article has been cited by other articles:

				J. R. Bading and A. F. Shields Imaging of Cell Proliferation: Status and Prospects J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S. [Abstract] [Full Text] [PDF]

				V. Ponomarev, M. Doubrovin, A. Shavrin, I. Serganova, T. Beresten, L. Ageyeva, C. Cai, J. Balatoni, M. Alauddin, and J. Gelovani A Human-Derived Reporter Gene for Noninvasive Imaging in Humans: Mitochondrial Thymidine Kinase Type 2 J. Nucl. Med., May 1, 2007; 48(5): 819 - 826. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, K. A. Krohn, S. M. Larson, R. Weissleder, D. A. Mankoff, J. M. Hoffman, J. M. Link, K. Z. Guyton, W. C. Eckelman, H. I. Scher, et al. The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development Clin. Cancer Res., November 15, 2005; 11(22): 7967 - 7985. [Abstract] [Full Text] [PDF]

				S. Nimmagadda, T. J. Mangner, H. Sun, R. W. Klecker Jr., O. Muzik, J. M. Lawhorn-Crews, K. A. Douglas, J. M. Collins, and A. F. Shields Biodistribution and Radiation Dosimetry Estimates of 1-(2'-Deoxy-2'-18F-Fluoro-1-{beta}-D-Arabinofuranosyl)-5-Bromouracil: PET Imaging Studies in Dogs J. Nucl. Med., November 1, 2005; 46(11): 1916 - 1922. [Abstract] [Full Text] [PDF]

				J. L. Schwartz, Y. Tamura, R. Jordan, J. R. Grierson, and K. A. Krohn Monitoring Tumor Cell Proliferation by Targeting DNA Synthetic Processes with Thymidine and Thymidine Analogs J. Nucl. Med., December 1, 2003; 44(12): 2027 - 2032. [Abstract] [Full Text] [PDF]

				T. Miyagawa, T. Oku, T. Sasajima, R. Dasai, B. Beattie, R. Finn, J. G. Tjuvajev, and R. Blasberg Assessment of Treatment Response by Autoradiography with 14C-Aminocyclopentane Carboxylic Acid, 67Ga-DTPA, and 18F-FDG in a Herpes Simplex Virus Thymidine Kinase/Ganciclovir Brain Tumor Model J. Nucl. Med., November 1, 2003; 44(11): 1845 - 1854. [Abstract] [Full Text] [PDF]

				J. Toyohara, A. Gogami, A. Hayashi, Y. Yonekura, and Y. Fujibayashi Pharmacokinetics and Metabolism of 5-125I-Iodo-4'-Thio-2'-Deoxyuridine in Rodents J. Nucl. Med., October 1, 2003; 44(10): 1671 - 1676. [Abstract] [Full Text] [PDF]

				A. K. Buck, G. Halter, H. Schirrmeister, J. Kotzerke, I. Wurziger, G. Glatting, T. Mattfeldt, B. Neumaier, S. N. Reske, and M. Hetzel Imaging Proliferation in Lung Tumors with PET: 18F-FLT Versus 18F-FDG J. Nucl. Med., September 1, 2003; 44(9): 1426 - 1431. [Abstract] [Full Text] [PDF]

				A. F. Shields PET Imaging with 18F-FLT and Thymidine Analogs: Promise and Pitfalls J. Nucl. Med., September 1, 2003; 44(9): 1432 - 1434. [Full Text] [PDF]

				U. Roelcke, O. Hausmann, A. Merlo, J. Missimer, R. P. Maguire, P. Freitag, E. W. Radu, R. Weinreich, O. Gratzl, and K. L. Leenders PET Imaging Drug Distribution After Intratumoral Injection: The Case for 124I-Iododeoxyuridine in Malignant Gliomas J. Nucl. Med., November 1, 2002; 43(11): 1444 - 1451. [Abstract] [Full Text] [PDF]

				H. Vesselle, J. Grierson, M. Muzi, J. M. Pugsley, R. A. Schmidt, P. Rabinowitz, L. M. Peterson, E. Vallieres, and D. E. Wood In Vivo Validation of 3'deoxy-3'-[18F]fluorothymidine ([18F]FLT) as a Proliferation Imaging Tracer in Humans: Correlation of [18F]FLT Uptake by Positron Emission Tomography with Ki-67 Immunohistochemistry and Flow Cytometry in Human Lung Tumors Clin. Cancer Res., November 1, 2002; 8(11): 3315 - 3323. [Abstract] [Full Text] [PDF]

				P. Wells, R. N. Gunn, M. Alison, C. Steel, M. Golding, A. S. Ranicar, F. Brady, S. Osman, T. Jones, and P. Price Assessment of Proliferation in Vivo Using 2-[11C]Thymidine Positron Emission Tomography in Advanced Intra-abdominal Malignancies Cancer Res., October 15, 2002; 62(20): 5698 - 5702. [Abstract] [Full Text] [PDF]

				J. S. Rasey, J. R. Grierson, L. W. Wiens, P. D. Kolb, and J. L. Schwartz Validation of FLT Uptake as a Measure of Thymidine Kinase-1 Activity in A549 Carcinoma Cells J. Nucl. Med., September 1, 2002; 43(9): 1210 - 1217. [Abstract] [Full Text] [PDF]

				J. Toyohara, A. Hayashi, M. Sato, H. Tanaka, K. Haraguchi, Y. Yoshimura, Y. Yonekura, and Y. Fujibayashi Rationale of 5-125I-Iodo-4'-Thio-2'-Deoxyuridine as a Potential Iodinated Proliferation Marker J. Nucl. Med., September 1, 2002; 43(9): 1218 - 1226. [Abstract] [Full Text] [PDF]

				Y. M. Dupertuis, M. Vazquez, J.-P. Mach, N. De Tribolet, C. Pichard, D. O. Slosman, and F. Buchegger Fluorodeoxyuridine Improves Imaging of Human Glioblastoma Xenografts with Radiolabeled Iododeoxyuridine Cancer Res., November 1, 2001; 61(21): 7971 - 7977. [Abstract] [Full Text] [PDF]